Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
60 hedge funds and large institutions have $125M invested in Seelos Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 7 closing their positions.
950% more capital invested
Capital invested by funds: $11.9M → $125M (+$113M)
486% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 7
131% more funds holding
Funds holding: 26 → 60 (+34)
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
50% less call options, than puts
Call options by funds: $837K | Put options by funds: $1.67M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$10.5M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$6.57M |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$5.74M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$5.23M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$4.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
-$1.21M |
| 2 |
Renaissance Technologies
New York
|
-$1.11M |
| 3 |
Squarepoint
New York
|
-$397K |
| 4 |
VF
Virtu Financial
New York
|
-$134K |
| 5 |
AMC
Asset Management Corp
Northbrook,
Illinois
|
-$128K |
SEEL Hedge Fund Activity: Q1 2021 in Review
60 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q1 2021, worth a combined $125M — up 950% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new SEEL positions and 7 closed out — a net gain of 34 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $10.5M. The largest seller was Uniplan Investment Counsel, cutting an estimated $1.21M.
- 60 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q1 2021, up from 26 in Q4 2020.
- Funds reported $125M of Seelos Therapeutics, Inc. Common Stock stock for Q1 2021, up 950% quarter-over-quarter.
- 41 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q1 2021 and 7 closed out, a net change of +34 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q1 2021 was Invesco, an estimated $10.5M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q1 2021 was Uniplan Investment Counsel, an estimated $1.21M sold.
Based on aggregated 13F filings for Q1 2021.